Optellum Expands AI Lung Cancer Diagnostics to 250 Sites
Optellum 將 AI 肺癌診斷技術擴展至 250 個站點
更新於: 2026年6月5日 上午07:00
Optellum, a medical technology leader based in Oxford and Houston, has reached a significant milestone: its AI-powered lung cancer diagnostic platform is now active in over 250 clinical sites worldwide.
位於牛津與休士頓的醫療技術領導者 Optellum 達成了一項重大里程碑：其以人工智慧(AI)驅動的肺癌診斷平台，目前已在全球超過 250 個臨床據點啟用。
At the heart of this growth is the Virtual Nodule Clinic (VNC), an innovative software that assists clinicians by analyzing CT scans to identify and assess lung nodules.
這項成長的核心在於「虛擬結節診所」(Virtual Nodule Clinic, VNC)，這是一款創新軟體，透過分析電腦斷層掃描(CT)來協助臨床醫師識別並評估肺部結節。
Using advanced 'Lung Cancer Prediction' AI, the system assigns a malignancy risk score to nodules within seconds and utilizes natural language processing to ensure no incidental findings are missed.
該系統運用先進的「肺癌預測」人工智慧，能在數秒內為結節分配惡性風險評分，並利用自然語言處理(NLP)技術，確保不遺漏任何偶發性發現。
As the first FDA-cleared and CE-marked tool of its kind, Optellum has already processed over 3 million patient cases.
作為首款獲得 FDA 許可與 CE 標章的同類工具，Optellum 已處理過超過 300 萬例病患案例。
The company is now evolving its technology into 'LungOS®,' a comprehensive operating system for thoracic care that integrates diagnostic precision with clinical workflows.
該公司正將其技術演進為「LungOS®」，這是一個整合診斷精確度與臨床工作流程的胸腔護理全面作業系統。
Through strategic partnerships with major entities like GE HealthCare and the NHS, Optellum is transforming lung cancer detection from a manual process into a highly efficient, AI-augmented standard of care.
透過與 GE HealthCare 和英國國家醫療服務體系(NHS)等大型機構的策略合作，Optellum 正將肺癌檢測從人工程序轉變為高度高效、人工智慧輔助的醫療護理標準。
This expansion signals a major step forward in global medical technology, moving AI from experimental research into essential, life-saving hospital practice.
此次擴張象徵全球醫療技術邁出重大的一步，將人工智慧從實驗研究推向醫院中至關重要、能拯救生命的實務應用。
